Showing results (201-210 of 1,869) with videos related to
Sort By:
Pageof 187
Current Cancer Drug Targets|January 22, 2010
Bid mediates anti-apoptotic COX-2 induction through the IKKbeta/NFkappaB pathway due to 5-MCDE exposureWenjing Luo, Jingxia Li, Dongyun Zhang, et al.Current Cancer Drug Targets|January 22, 2010
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patientsAnnamaria Ruzzo, Francesco Graziano, Emanuele Canestrari, et al.Current Cancer Drug Targets|January 22, 2010
Gammadelta T cell modulation in anticancer treatmentNadia Caccamo, Francesco Dieli, Serena Meraviglia, et al.Current Cancer Drug Targets|January 22, 2010
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell functionA K Gandhi, J Kang, L Capone, et al.Current Cancer Drug Targets|May 2, 2018
Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysisBing-Di Yan, Xiao-Feng Cong, Sha-Sha Zhao, et al.Current Cancer Drug Targets|May 2, 2018
Cutaneous Application of Celecoxib for Inflammatory and Cancer DiseasesOliesia Gonzalez Quiñones, Maria Bernadete Riemma PierreCurrent Cancer Drug Targets|June 1, 2018
Malignant Intracranial High Grade Glioma and Current Treatment StrategyXiang Zhang, Wei Zhang, Xing-Gang Mao, et al.Current Cancer Drug Targets|March 12, 2009
Assessment of the mitotic spindle assembly checkpoint (SAC) as the target of anticancer therapiesVictor M Bolanos-GarciaCurrent Cancer Drug Targets|March 12, 2009
The novel RARbeta isoform (beta5) is a potential target of retinoids in breast cancerKonstantin ChristovCurrent Cancer Drug Targets|March 12, 2009
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancerPhilippe L Bedard, Evandro de Azambuja, Fatima CardosoPageof 187